Comment from Par Sterile Products, LLC (Latham & Watkins LLP)

Summary: Latham & Watkins LLP, representing their client Par Sterile Products, LLC, opposes the nomination of vasopressin to the FDA's list of bulk drug substances for compounding. They argue that there is no clinical need for a compounded version of the drug, that it poses significant safety risks, and that it would essentially be a copy of an already FDA-approved product (Vasostrict®).